

PATENT PATENT ATTORNEY DOCKET NO. 50211/006002 5.8.

Certificate of Mailing: Date of Dep	osit:April 30, 2003
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Commissioner	
for Patents, Washington, D.C. 20231.	
Susan M. Cannon Printed name of person mailing corréspondence	Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Judes Poirier

Art Unit:

1648

Serial No.:

09/500,162

Examiner:

Parkin, Jeffrey S.

Filed:

February 8, 2000

Customer No.:

21559

Title:

PHARMACOGENETIC METHODS FOR USE IN THE

TREATMENT OF NERVOUS SYSTEM DISEASE

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee of 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 30 April 2003

Clark & Elbing LLP 101 Federal Street Boston, MA 02110 Telephone: 617-428-0200

Facsimile: 617-428-7045 50211.006002 Supplemental IDS.doc

KALEN L. ELBING REG NO 35,239 EM

ristina Bieker-Brady Ph.D.

Reg. No. 39,109

21559

PATENT TRADEMARK OFFICE